Glomerulonephritis - Pipeline Review, H2 2017

Published by Global Markets Direct on 19th September 2017 | Ref: 635751 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Glomerulonephritis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H2 2017, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 5, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).

- The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Glomerulonephritis - Overview 6

Glomerulonephritis - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Glomerulonephritis - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 18

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Glomerulonephritis - Companies Involved in Therapeutics Development 25

Achillion Pharmaceuticals Inc 25

Anthera Pharmaceuticals Inc 25

Biogen Inc 26

Bristol-Myers Squibb Company 26

Cellmid Ltd 27

ChemoCentryx Inc 27

Complexa Inc 28

Dimerix Bioscience Pty Ltd 28

GlaxoSmithKline Plc 28

Merck KGaA 29

Omeros Corp 30

Pfizer Inc 30

Pharmalink AB 31

Ra Pharmaceuticals Inc 31

Retrophin Inc 32

Rigel Pharmaceuticals Inc 32

Shire Plc 33

Visterra Inc 33

Glomerulonephritis - Drug Profiles 34

(irbesartan + propagermanium) - Drug Profile 34

abatacept - Drug Profile 38

ACH-4471 - Drug Profile 47

ACH-5228 - Drug Profile 50

AMY-101 - Drug Profile 51

atacicept - Drug Profile 53

avacopan - Drug Profile 56

AVX-002 - Drug Profile 63

BaxB-01 - Drug Profile 64

BaxG-03 - Drug Profile 66

belimumab - Drug Profile 68

blisibimod - Drug Profile 75

budesonide - Drug Profile 83

CAB-102 - Drug Profile 86

CCX-140 - Drug Profile 88

CXA-10 - Drug Profile 92

ERG-240 - Drug Profile 94

fostamatinib disodium - Drug Profile 95

losmapimod - Drug Profile 101

Monoclonal Antibodies to Inhibit ITGAM for Cardiovascular, Immunology and Kidney Diseases - Drug Profile 104

OMS-721 - Drug Profile 105

PBF-677 - Drug Profile 115

PF-06730512 - Drug Profile 116

PF-1355 - Drug Profile 117

Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile 118

rituximab - Drug Profile 119

SHP-627 - Drug Profile 126

Small Molecule to Inhibit Factor D for C3 glomerulopathy and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 128

sparsentan - Drug Profile 129

Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile 133

TM-5484 - Drug Profile 134

Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 135

VAR-200 - Drug Profile 136

VIS-649 - Drug Profile 137

Glomerulonephritis - Dormant Projects 138

Glomerulonephritis - Discontinued Products 140

Glomerulonephritis - Product Development Milestones 141

Featured News & Press Releases 141

Appendix 153

Methodology 153

Coverage 153

Secondary Research 153

Primary Research 153

Expert Panel Validation 153

Contact Us 153

Disclaimer 154

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

635751 | GMDHC9725IDB

Number of Pages

157

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
18-11-2019

$2,000 USD

Published by Global Markets Direct
18-09-2018

$2,000 USD

Published by Global Markets Direct
20-03-2018

$2,000 USD

Published by Global Data
30-08-2017

$2,500 USD

Published by Global Markets Direct
28-04-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Glomerulonephritis - Pipeline Review, H2 2017 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.